Louisiana legislators may not have learned their lesson as they try to put taxpayers on the hook for a new Medicaid benefit that may end up causing any or all of wasted money, much higher expenses, and potentially avoidable harm to recipients.
Last year, a line item tucked into the state’s general appropriation bill would have made funding available to give semaglutide, a receptor agonist for human glucagon-like peptide-1 which is the basis for several drugs such as Wegovy, Ozempic, Monjauro, and Rybelus, to state employees that suffered from obesity. Republican Gov. Jeff Landry vetoed that.
And wisely so, for the monthly injections would have imposed a tremendous cost that must continue for effectiveness to kick in and stay in. Lifestyle changes, of which Landry has signaled at least indirect support for through his healthy eating initiatives, would just as effective if not even more so for weight loss and shedding of problems related to obesity. It would cost the state little to engage in campaigns urging personal responsibility to eat right and less, and to exercise more.